Every week, about 200 people are newly diagnosed with multiple sclerosis, and about 400,000 Americans are affected by the autoimmune disease.

So far, no one treatment works on all patients. But our sister-publication, Boca Raton magazine, just forwarded us a release from The Scripps Research Institute about their development of a drug that may work on more patients than ever.

The new therapy, which shuts down a type of white blood cell called TH17, has proven effective in mice. The cell malfunctions in patients with MS, and when blocked, MS symptoms in mice disappeared. If it works in humans, it could also have several advantages over MS drugs currently on the market: could be taken in pill form rather than injected and it would single out TH17 cells, leaving other cells alone—decreasing side effects.

The new treatment is already garnering interest from drug companies.

Professor in the Department of Molecular Therapeutics at Scripps is leading the team investigating the drug.

Click here to read more about the drug and for quotes directly from Burris on his team's research.

Scripps researchers also recently discovered a known enzyme protects against measles by altering the virus' genetic material and a potent new class of compounds has the potential to fight cancer and Alzheimer's disease.

Click here to read about all of Scripps' current research.

You can support MS research in Utah by running through the mud. Mud Run MS is on August 13, hosted by Miller Motorsports Park. Click here for more info.